NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...

In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers. Last reviewed: 19 June 2025 Guidance development process LSA guidance evaluates categories of ...

Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults. Last reviewed: 19 June 2025 Next review: This guidance will be ...

Evaluation committee members The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a streamlined evaluation by the lead team of committee D, ...

Capacity impact The capacity impact of this topic will have been realised while the treatment has been in the Cancer Drugs Fund. So, no significant change in capacity is anticipated. Localities can ...

Atezolizumab (Tecentriq, Roche) is indicated for 'adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its ...

4 Committee members This topic was considered by NICE's medical technologies advisory committee, which is a standing advisory committee of NICE. Committee members are asked to declare any interests in ...